Letrozole vs Clomiphene for Ovulation Induction: What Distributors Should Know

Letrozole and clomiphene citrate are both first-line ovulation induction agents, but they work by different mechanisms and Indian prescribing has shifted steadily toward letrozole in PCOS. A gynae distributor needs both — carrying one and not the other closes you out of half the conversations in a fertility clinic. Halefem supplies letrozole as HALTRO and clomiphene citrate as CLOMIHAL and CLOMIHAL U 100.

How they differ

Clomiphene citrate

A selective oestrogen receptor modulator. It blocks oestrogen receptors at the hypothalamus, so the brain reads oestrogen as low and increases GnRH, which raises FSH and drives follicular development.

It is the older agent, extremely well established, inexpensive and familiar to every gynaecologist in the country. Its known drawback is that the same receptor blockade acts on the endometrium and cervical mucus, which is why some patients ovulate but do not conceive — a thin endometrium is a recognised limitation.

Letrozole

An aromatase inhibitor. It reduces the conversion of androgens to oestrogen, lowering circulating oestrogen and prompting the same rise in FSH — but without blocking oestrogen receptors.

Because it is not a receptor blocker and has a shorter half-life, it does not carry the same anti-oestrogenic effect on the endometrium. It also tends to produce monofollicular development, which matters for multiple-pregnancy risk.

Letrozole was developed as a breast cancer drug and its use in ovulation induction is well established in practice worldwide, including in Indian fertility centres. A distributor should be aware that its regulatory status for this indication has been debated in India over the years; prescribing decisions belong entirely to the treating clinician.

Why the prescribing shifted

Evidence in PCOS-related anovulation has generally favoured letrozole on live birth rates compared with clomiphene, and the endometrial argument is intuitive to clinicians. In practice most Indian fertility clinics now use letrozole first-line for PCOS, while clomiphene remains widely used — particularly by general gynaecologists, in unexplained infertility protocols, and where cost is the deciding factor.

For a distributor the practical conclusion is simple. This is not a market where one product replaces the other. The prescriber base splits, often within the same city: the IVF centre writes letrozole, the district hospital OPD still writes clomiphene, and you want to supply both.

What this means commercially

Ovulation induction agents sit in the middle of a protocol rather than at the end of one. A patient on letrozole is usually also on myo-inositol for insulin sensitivity, often a progesterone for luteal support after ovulation, and frequently an antenatal supplement once conception occurs.

That is the real opportunity. A distributor who can supply the whole protocol becomes the default supplier for that clinic, rather than one of three people servicing different fragments of it. It is also why fertility clinics are worth disproportionate effort: a small number of prescribers generate long, layered, repeating prescriptions.

Strengths and why CLOMIHAL U 100 exists

Clomiphene is conventionally used at a starting dose that may be escalated in resistant cases. Carrying more than one strength means a partner can serve both routine and step-up prescribing without sending the doctor to a second supplier — which is the reason CLOMIHAL and CLOMIHAL U 100 sit alongside each other in the Halefem range.

The same logic runs through the female infertility and PCOS-PCOD series: myo-inositol (CYSTOFEM), letrozole (HALTRO), clomiphene citrate (CLOMIHAL, CLOMIHAL U 100), DHEA for poor ovarian reserve (OVADONE) and hCG injection for trigger. It is assembled to cover a protocol, not to fill a catalogue.

Handling and packing

Both molecules are tablets and both are moisture-sensitive enough to justify Alu-Alu rather than PVC. hCG injection, which frequently accompanies them in an induction cycle, is a Schedule C and C(1) product requiring a Form 21B licence and appropriate cold-chain handling. See the documents required.

Frequently asked questions

What is the difference between letrozole and clomiphene citrate?

Clomiphene is a selective oestrogen receptor modulator that blocks oestrogen receptors at the hypothalamus. Letrozole is an aromatase inhibitor that reduces oestrogen production. Both raise FSH and induce ovulation, but letrozole avoids the anti-oestrogenic effect on the endometrium associated with clomiphene.

Why is letrozole often preferred in PCOS?

Evidence in PCOS-related anovulation has generally favoured letrozole on live birth rates, and it avoids clomiphene’s thinning effect on the endometrium. It also tends to produce monofollicular development. Prescribing decisions rest with the treating clinician.

Is clomiphene citrate still used in India?

Yes, widely. It remains familiar, inexpensive and effective, and is commonly used by general gynaecologists and in protocols outside PCOS. A gynae distributor should carry both molecules rather than choosing between them.

Why does Halefem carry two clomiphene strengths?

Because clomiphene dosing may be escalated in resistant cases. Carrying CLOMIHAL and CLOMIHAL U 100 means a partner can supply both routine and step-up prescribing without the doctor going to another company.

Are ovulation induction products available for PCD franchise in India?

Yes. Halefem supplies letrozole, clomiphene citrate, myo-inositol, DHEA and hCG injection to franchise partners across India with monopoly rights district by district. A drug licence and GST registration are required, and Form 21B specifically for the injectables.

Available for gynae PCD franchise across India

Halefem Gynae markets 200+ gynae formulations across six therapeutic series to franchise partners across India, one partner per district. A valid drug licence and GST registration in your own name are required before we can supply.

Call +91-9888020547 to check whether your district is open, or read about the gynae PCD pharma franchise, documents required, monopoly rights, what it costs to start, and the full gynae product range. Price list on request.

Halefem Gynae — a gynae division of Edmund Healthcare Pvt. Ltd., an ISO 9001:2015 certified company. Products manufactured at WHO-GMP compliant units, Sai Road, Baddi, Himachal Pradesh.

Written for pharmaceutical distributors and healthcare professionals in India. Not medical advice; prescribing decisions rest with the treating clinician.

\n